TABLE 2.
Paired baseline and follow‐up scores for outcome measures: Fibromyalgia Symptom Severity, Single‐Item Sleep Quality Scale (SQS), Patients’ Global Impression of Change (PGIC), General Anxiety Disorder‐7 (GAD‐7), Visual Analogue Scale‐Pain (VAS‐Pain), and EQ‐5D‐5L index value and subcomponents at 1, 3, 6, and 12 months.
| PROMs | Follow‐up | n | Scores at baseline | Scores at follow‐up | p‐value | Effect size (r) |
|---|---|---|---|---|---|---|
| Fibromyalgia Symptom Severity | 1 month | 231 | 23.00 (19.00–28.00) | 20.00 (15.00–25.00) | <.001 | –.49 |
| 3 months | 170 | 22.00 (18.00–27.00) | 19.00 (15.00–24.00) | <.001 | –.21 | |
| 6 months | 100 | 20.00 (16.25–25.00) | 17.00 (14.00–24.00) | <.001 | –.39 | |
| 12 months | 27 | 20.00 (16.00–27.00) | 17.00 (13.00–21.00) | .999 | –.43 | |
| SQS | 1 month | 247 | 3.00 (2.00–5.00) | 5.00 (3.00–7.00) | <.001 | –.29 |
| 3 months | 189 | 4.00 (2.00–6.00) | 6.00 (3.00–7.00) | <.001 | –.16 | |
| 6 months | 111 | 4.00 (3.00–6.00) | 6.00 (4.00–8.00) | <.001 | –.18 | |
| 12 months | 34 | 4.50 (3.00–6.00) | 6.00 (4.00–8.00) | .360 | –.09 | |
| PGIC | 1 month | 245 | – | 5.00 (4.00–6.00) | – | – |
| 3 months | 183 | – | 5.00 (4.00–6.00) | – | – | |
| 6 months | 116 | – | 6.00 (5.00–6.00) | – | – | |
| 12 months | 37 | – | 6.00 (5.00–6.00) | – | – | |
| GAD‐7 | 1 month | 252 | 8.00 (3.00–14.00) | 6.00 (3.00–10.00) | <.001 | –.30 |
| 3 months | 188 | 7.00 (3.00–12.00) | 6.00 (2.25–9.00) | <.001 | –.27 | |
| 6 months | 114 | 6.00 (2.00–11.00) | 5.00 (1.00–9.00) | .320 | –.25 | |
| 12 months | 37 | 4.00 (2.00–10.50) | 3.00 (1.00–6.00) | .999 | –.34 | |
| VAS‐Pain | 1 month | 246 | 7.00 (6.00–8.00) | 7.00 (5.00–8.00) | <.001 | –.35 |
| 3 months | 183 | 7.00 (6.00–8.00) | 6.00 (5.00–8.00) | <.001 | –.37 | |
| 6 months | 110 | 7.00 (5.00–8.00) | 6.00 (4.00–7.00) | <.001 | –.32 | |
| 12 months | 34 | 7.00 (5.75–8.00) | 7.00 (4.00–8.00) | .999 | –.18 | |
| EQ‐5D‐5L Mobility | 1 month | 250 | 3.00 (2.00–4.00) | 3.00 (2.00–3.00) | <.001 | –.27 |
| 3 months | 186 | 3.00 (2.00–4.00) | 3.00 (2.00–3.00) | .200 | –.20 | |
| 6 months | 113 | 3.00 (2.00–4.00) | 2.00 (2.00–3.00) | <.001 | –.33 | |
| 12 months | 36 | 3.00 (2.00–4.00) | 3.00 (2.00–3.00) | .999 | –.26 | |
| EQ‐5D‐5L Self‐Care | 1 month | 250 | 3.00 (2.00–3.00) | 2.00 (1.00–3.00) | <.001 | –.27 |
| 3 months | 186 | 2.00 (2.00–3.00) | 2.00 (1.00–3.00) | <.001 | –.24 | |
| 6 months | 113 | 2.00 (1.50–3.00) | 2.00 (1.00–3.00) | <.001 | –.33 | |
| 12 months | 36 | 2.00 (2.00–3.00) | 2.00 (1.00–3.00) | .160 | –.48 | |
| EQ‐5D‐5L Usual Activities | 1 month | 250 | 3.00 (3.00–4.00) | 3.00 (2.00–3.00) | <.001 | –.38 |
| 3 months | 186 | 3.00 (2.00–4.00) | 3.00 (2.00–3.00) | <.001 | –.34 | |
| 6 months | 113 | 3.00 (2.00–4.00) | 3.00 (2.00–3.00) | <.001 | –.35 | |
| 12 months | 36 | 3.00 (2.25–4.00) | 3.00 (2.00–3.00) | .999 | –.31 | |
| EQ‐5D‐5L Pain and Discomfort | 1 month | 250 | 4.00 (3.00–4.00) | 3.00 (3.00–4.00) | <.001 | –.49 |
| 3 months | 186 | 3.00 (3.00–4.00) | 3.00 (2.75–4.00) | <.001 | –.44 | |
| 6 months | 113 | 4.00 (3.00–4.00) | 3.00 (2.00–3.00) | <.001 | –.53 | |
| 12 months | 36 | 4.00 (3.00–4.00) | 3.00 (3.00–3.00) | .080 | –.50 | |
| EQ‐5D‐5L Anxiety and Depression | 1 month | 250 | 3.00 (2.00–4.00) | 2.00 (2.00–3.00) | <.001 | –.27 |
| 3 months | 186 | 3.00 (2.00–3.00) | 2.00 (1.00–3.00) | <.001 | –.25 | |
| 6 months | 113 | 2.00 (1.00–3.00) | 2.00 (1.00–3.00) | <.001 | –.40 | |
| 12 months | 36 | 2.00 (1.00–3.00) | 2.00 (1.00–3.00) | .999 | –.32 | |
| EQ‐5D‐5L Index Value | 1 month | 250 | 0.33 (0.08–0.54) | 0.53 (0.27–0.63) | <.001 | –.39 |
| 3 months | 186 | 0.34 (0.10–0.56) | 0.54 (0.26–0.65) | <.001 | –.34 | |
| 6 months | 113 | 0.38 (0.18–0.62) | 0.56 (0.41–0.69) | <.001 | –.39 | |
| 12 months | 36 | 0.36 (0.21–0.61) | 0.55 ( 0.40–0.67) | <.001 | –.40 |
Note: p <.05.